nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Tearing eyes—Docetaxel—head and neck cancer	0.104	0.104	CcSEcCtD
Gadoteridol—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.0298	0.0298	CcSEcCtD
Gadoteridol—Tingling sensation—Fluorouracil—head and neck cancer	0.0294	0.0294	CcSEcCtD
Gadoteridol—Lacrimation increased—Fluorouracil—head and neck cancer	0.0256	0.0256	CcSEcCtD
Gadoteridol—Face oedema—Hydroxyurea—head and neck cancer	0.023	0.023	CcSEcCtD
Gadoteridol—Rash maculo-papular—Fluorouracil—head and neck cancer	0.0215	0.0215	CcSEcCtD
Gadoteridol—Lacrimation increased—Docetaxel—head and neck cancer	0.0185	0.0185	CcSEcCtD
Gadoteridol—Injection site reaction—Docetaxel—head and neck cancer	0.017	0.017	CcSEcCtD
Gadoteridol—Cardiac arrest—Fluorouracil—head and neck cancer	0.0163	0.0163	CcSEcCtD
Gadoteridol—Fluid retention—Docetaxel—head and neck cancer	0.0162	0.0162	CcSEcCtD
Gadoteridol—Dysphagia—Fluorouracil—head and neck cancer	0.0148	0.0148	CcSEcCtD
Gadoteridol—Ill-defined disorder—Vinblastine—head and neck cancer	0.0146	0.0146	CcSEcCtD
Gadoteridol—Erythema—Hydroxyurea—head and neck cancer	0.0144	0.0144	CcSEcCtD
Gadoteridol—Malaise—Vinblastine—head and neck cancer	0.0142	0.0142	CcSEcCtD
Gadoteridol—Convulsion—Vinblastine—head and neck cancer	0.0136	0.0136	CcSEcCtD
Gadoteridol—Hypertension—Vinblastine—head and neck cancer	0.0136	0.0136	CcSEcCtD
Gadoteridol—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0133	0.0133	CcSEcCtD
Gadoteridol—Discomfort—Vinblastine—head and neck cancer	0.0132	0.0132	CcSEcCtD
Gadoteridol—Malaise—Hydroxyurea—head and neck cancer	0.0129	0.0129	CcSEcCtD
Gadoteridol—Convulsion—Hydroxyurea—head and neck cancer	0.0124	0.0124	CcSEcCtD
Gadoteridol—Discomfort—Hydroxyurea—head and neck cancer	0.0121	0.0121	CcSEcCtD
Gadoteridol—Rhinitis—Fluorouracil—head and neck cancer	0.0119	0.0119	CcSEcCtD
Gadoteridol—Oedema—Hydroxyurea—head and neck cancer	0.0117	0.0117	CcSEcCtD
Gadoteridol—Paraesthesia—Vinblastine—head and neck cancer	0.0115	0.0115	CcSEcCtD
Gadoteridol—Pain—Vinblastine—head and neck cancer	0.011	0.011	CcSEcCtD
Gadoteridol—Dysphagia—Docetaxel—head and neck cancer	0.0107	0.0107	CcSEcCtD
Gadoteridol—Feeling abnormal—Vinblastine—head and neck cancer	0.0106	0.0106	CcSEcCtD
Gadoteridol—Dyspnoea—Hydroxyurea—head and neck cancer	0.0104	0.0104	CcSEcCtD
Gadoteridol—Erythema—Fluorouracil—head and neck cancer	0.0103	0.0103	CcSEcCtD
Gadoteridol—Abdominal pain—Vinblastine—head and neck cancer	0.0102	0.0102	CcSEcCtD
Gadoteridol—Pain—Hydroxyurea—head and neck cancer	0.01	0.01	CcSEcCtD
Gadoteridol—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00966	0.00966	CcSEcCtD
Gadoteridol—Hypersensitivity—Vinblastine—head and neck cancer	0.00947	0.00947	CcSEcCtD
Gadoteridol—Body temperature increased—Hydroxyurea—head and neck cancer	0.00926	0.00926	CcSEcCtD
Gadoteridol—Convulsion—Fluorouracil—head and neck cancer	0.00895	0.00895	CcSEcCtD
Gadoteridol—Chest pain—Fluorouracil—head and neck cancer	0.0088	0.0088	CcSEcCtD
Gadoteridol—Diarrhoea—Vinblastine—head and neck cancer	0.00879	0.00879	CcSEcCtD
Gadoteridol—Discomfort—Fluorouracil—head and neck cancer	0.00869	0.00869	CcSEcCtD
Gadoteridol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00863	0.00863	CcSEcCtD
Gadoteridol—Rhinitis—Docetaxel—head and neck cancer	0.00859	0.00859	CcSEcCtD
Gadoteridol—Dizziness—Vinblastine—head and neck cancer	0.0085	0.0085	CcSEcCtD
Gadoteridol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00843	0.00843	CcSEcCtD
Gadoteridol—Oedema—Fluorouracil—head and neck cancer	0.00843	0.00843	CcSEcCtD
Gadoteridol—Vomiting—Vinblastine—head and neck cancer	0.00817	0.00817	CcSEcCtD
Gadoteridol—Headache—Vinblastine—head and neck cancer	0.00805	0.00805	CcSEcCtD
Gadoteridol—Diarrhoea—Hydroxyurea—head and neck cancer	0.00802	0.00802	CcSEcCtD
Gadoteridol—Flushing—Docetaxel—head and neck cancer	0.00795	0.00795	CcSEcCtD
Gadoteridol—Hypotension—Fluorouracil—head and neck cancer	0.00788	0.00788	CcSEcCtD
Gadoteridol—Dizziness—Hydroxyurea—head and neck cancer	0.00775	0.00775	CcSEcCtD
Gadoteridol—Nausea—Vinblastine—head and neck cancer	0.00763	0.00763	CcSEcCtD
Gadoteridol—Paraesthesia—Fluorouracil—head and neck cancer	0.00757	0.00757	CcSEcCtD
Gadoteridol—Dyspnoea—Fluorouracil—head and neck cancer	0.00752	0.00752	CcSEcCtD
Gadoteridol—Erythema—Docetaxel—head and neck cancer	0.00746	0.00746	CcSEcCtD
Gadoteridol—Vomiting—Hydroxyurea—head and neck cancer	0.00745	0.00745	CcSEcCtD
Gadoteridol—Rash—Hydroxyurea—head and neck cancer	0.00739	0.00739	CcSEcCtD
Gadoteridol—Dermatitis—Hydroxyurea—head and neck cancer	0.00738	0.00738	CcSEcCtD
Gadoteridol—Headache—Hydroxyurea—head and neck cancer	0.00734	0.00734	CcSEcCtD
Gadoteridol—Dysgeusia—Docetaxel—head and neck cancer	0.0073	0.0073	CcSEcCtD
Gadoteridol—Pain—Fluorouracil—head and neck cancer	0.00721	0.00721	CcSEcCtD
Gadoteridol—Nausea—Hydroxyurea—head and neck cancer	0.00696	0.00696	CcSEcCtD
Gadoteridol—Feeling abnormal—Fluorouracil—head and neck cancer	0.00695	0.00695	CcSEcCtD
Gadoteridol—Urticaria—Fluorouracil—head and neck cancer	0.0067	0.0067	CcSEcCtD
Gadoteridol—Syncope—Docetaxel—head and neck cancer	0.00669	0.00669	CcSEcCtD
Gadoteridol—Body temperature increased—Fluorouracil—head and neck cancer	0.00667	0.00667	CcSEcCtD
Gadoteridol—Loss of consciousness—Docetaxel—head and neck cancer	0.00656	0.00656	CcSEcCtD
Gadoteridol—Cough—Docetaxel—head and neck cancer	0.00651	0.00651	CcSEcCtD
Gadoteridol—Convulsion—Docetaxel—head and neck cancer	0.00646	0.00646	CcSEcCtD
Gadoteridol—Hypertension—Docetaxel—head and neck cancer	0.00644	0.00644	CcSEcCtD
Gadoteridol—Chest pain—Docetaxel—head and neck cancer	0.00635	0.00635	CcSEcCtD
Gadoteridol—Hypersensitivity—Fluorouracil—head and neck cancer	0.00621	0.00621	CcSEcCtD
Gadoteridol—Dry mouth—Docetaxel—head and neck cancer	0.00621	0.00621	CcSEcCtD
Gadoteridol—Anaphylactic shock—Docetaxel—head and neck cancer	0.00609	0.00609	CcSEcCtD
Gadoteridol—Oedema—Docetaxel—head and neck cancer	0.00609	0.00609	CcSEcCtD
Gadoteridol—Shock—Docetaxel—head and neck cancer	0.00599	0.00599	CcSEcCtD
Gadoteridol—Pruritus—Fluorouracil—head and neck cancer	0.00597	0.00597	CcSEcCtD
Gadoteridol—Diarrhoea—Fluorouracil—head and neck cancer	0.00577	0.00577	CcSEcCtD
Gadoteridol—Hypotension—Docetaxel—head and neck cancer	0.00569	0.00569	CcSEcCtD
Gadoteridol—Dizziness—Fluorouracil—head and neck cancer	0.00558	0.00558	CcSEcCtD
Gadoteridol—Paraesthesia—Docetaxel—head and neck cancer	0.00547	0.00547	CcSEcCtD
Gadoteridol—Dyspnoea—Docetaxel—head and neck cancer	0.00543	0.00543	CcSEcCtD
Gadoteridol—Vomiting—Fluorouracil—head and neck cancer	0.00536	0.00536	CcSEcCtD
Gadoteridol—Rash—Fluorouracil—head and neck cancer	0.00532	0.00532	CcSEcCtD
Gadoteridol—Dermatitis—Fluorouracil—head and neck cancer	0.00531	0.00531	CcSEcCtD
Gadoteridol—Headache—Fluorouracil—head and neck cancer	0.00528	0.00528	CcSEcCtD
Gadoteridol—Pain—Docetaxel—head and neck cancer	0.00521	0.00521	CcSEcCtD
Gadoteridol—Feeling abnormal—Docetaxel—head and neck cancer	0.00502	0.00502	CcSEcCtD
Gadoteridol—Nausea—Fluorouracil—head and neck cancer	0.00501	0.00501	CcSEcCtD
Gadoteridol—Abdominal pain—Docetaxel—head and neck cancer	0.00481	0.00481	CcSEcCtD
Gadoteridol—Body temperature increased—Docetaxel—head and neck cancer	0.00481	0.00481	CcSEcCtD
Gadoteridol—Hypersensitivity—Docetaxel—head and neck cancer	0.00448	0.00448	CcSEcCtD
Gadoteridol—Pruritus—Docetaxel—head and neck cancer	0.00431	0.00431	CcSEcCtD
Gadoteridol—Diarrhoea—Docetaxel—head and neck cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Dizziness—Docetaxel—head and neck cancer	0.00403	0.00403	CcSEcCtD
Gadoteridol—Vomiting—Docetaxel—head and neck cancer	0.00387	0.00387	CcSEcCtD
Gadoteridol—Rash—Docetaxel—head and neck cancer	0.00384	0.00384	CcSEcCtD
Gadoteridol—Dermatitis—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Gadoteridol—Headache—Docetaxel—head and neck cancer	0.00381	0.00381	CcSEcCtD
Gadoteridol—Nausea—Docetaxel—head and neck cancer	0.00362	0.00362	CcSEcCtD
